FdaApplication
BLA 761035
Identifiers
- fda_app_no: BLA761035
Properties
| Property | Value |
|---|---|
| applicant_name | Bristol-Myers Squibb Company |
| application_type | BLA |
| approval_date | 2015-11-30 |
Revenue by product
EMPLICITI
| Period | Revenue |
|---|---|
| Q4 2022 | $71.0M |
| Q3 2022 | $73.0M |
| Q2 2022 | $77.0M |
| Q1 2022 | $75.0M |
| Q4 2021 | $81.0M |
| Q3 2021 | $82.0M |
| Q2 2021 | $86.0M |
| Q1 2021 | $85.0M |
| Q4 2020 | $91.0M |
| Q3 2020 | $96.0M |
| Q2 2020 | $97.0M |
| Q1 2020 | $97.0M |
| Q4 2019 | $94.0M |
| Q3 2019 | $89.0M |
| Q2 2019 | $91.0M |
| Q1 2019 | $83.0M |
| Q4 2018 | $69.0M |
| Q3 2018 | $59.0M |
| Q2 2018 | $64.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| EMPLICITI | ELOTUZUMAB | 300MG | For Injection |
| EMPLICITI | ELOTUZUMAB | 400MG | For Injection |
2 products